Field Study of a Digital Therapeutic Platform to Facilitate Treatment for Methamphetamine-Primary Stimulant Use Disorder
Completed · Not applicable
Conditions studied: Methamphetamine Abuse
In brief
The overall purpose of the observational, investigational pilot study is to assess the clinical utility of the Affect digital health platform (the Affect® "app") as part of the Affect program of treatment for methamphetamine-primary stimulant use disorder. The study also will identify elements of the Affect app that enhance engagement of participants in the study toward the goal of improving patient outcomes, including reduction/cessation of stimulant use.
Key facts
- Study ID
- NCT05266716
- Run by
- Affect Therapeutics, Inc.
- People needed
- 79
- Starts
- 2021-02-18
- Expected to finish
- 2022-01-07
- Last updated by the study team
- 2022-03-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Affect Therapeutics — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.